Registry update — unassessed
The Efficacy and Safety of a Mental Intervention Program vs. Usual Care and Nicotinamide Riboside (NR) vs. Placebo for Improving Health-related Quality of Life in Long Covid: A 2 x 2 Factorial Randomized Controlled Trial
Trial registry update: COMPLETED. No results reported in the supplied registry record.
RCTN=310Routine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 25, 2026 · Discovered: Sep 23, 2026 · Assessed: — · Research update
What it does not prove
- The study protocol describes planned methodology but provides no results, so no efficacy of NR or MBRT can be determined from this text
- The 2x2 factorial design allows comparison of NR versus placebo and MBRT versus usual care, but the text does not report whether either intervention improved quality of life or secondary outcomes
- The explorative objectives including subgroup effects, mediators, and predictors are listed as planned analyses but no findings are presented
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 310
- Duration
- 12 months
- Population
- Individuals (18-70 years) with confirmed Long COVID interfering negatively with daily activities
- Primary outcome
- Health-related quality of life measured by Medical Outcome Study 36-item short form (SF-36) general health subscore
- Effect size
- —
- Significance
- Not reported
- Journal
- University Hospital, Akershus
- Published
- Aug 25, 2026
Sources
Primary source
- University Hospital, Akershus ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The study is a randomized controlled trial featuring a 2 x 2 factorial design where MBRT is compared with usual care and NR is compared with placebo.
Eligible participants are individuals (18-70 years) with confirmed Long COVID interferring negatively with daily activities. A total of 310 participants will be enrolled.
After baseline assessment (T1), the participants will be randomized 1:1 for both treatment comparisons, resulting in four treatment groups: a) MBRT and NR; b) usual care and NR; c) MBRT and placebo; d) usual care and placebo.
All treatment periods last for three months, followed by primary endpoint assessment (T2). Total follow-up time is 12 months (T3).
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.